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Treatment of mice with S4B6 
IL‑2 complex prevents lethal 
toxoplasmosis via IL‑12‑ 
and IL‑18‑dependent 
interferon‑gamma production 
by non‑CD4 immune cells
Andreas Kupz1*, Saparna Pai1, Paul R. Giacomin1, Jennifer A. Whan2, Robert A. Walker1, 
Pierre‑Mehdi Hammoudi 3, Nicholas C. Smith 4,5,7 & Catherine M. Miller1,6,7
Toxoplasmic encephalitis is an AIDS‑defining condition. The decline of IFN‑γ‑producing  CD4+ T cells 
in AIDS is a major contributing factor in reactivation of quiescent Toxoplasma gondii to an actively 
replicating stage of infection. Hence, it is important to characterize CD4‑independent mechanisms 
that constrain acute T. gondii infection. We investigated the in vivo regulation of IFN‑γ production 
by  CD8+ T cells, DN T cells and NK cells in response to acute T. gondii infection. Our data show that 
processing of IFN‑γ by these non‑CD4 cells is dependent on both IL‑12 and IL‑18 and the secretion of 
bioactive IL‑18 in response to T. gondii requires the sensing of viable parasites by multiple redundant 
inflammasome sensors in multiple hematopoietic cell types. Importantly, our results show that 
expansion of  CD8+ T cells, DN T cells and NK cell by S4B6 IL‑2 complex pre‑treatment increases survival 
rates of mice infected with T. gondii and this is dependent on IL‑12, IL‑18 and IFN‑γ. Increased survival 
is accompanied by reduced pathology but is independent of expansion of  TReg cells or parasite burden. 
This provides evidence for a protective role of IL2C‑mediated expansion of non‑CD4 cells and may 
represent a promising lead to adjunct therapy for acute toxoplasmosis.
Toxoplasma gondii (T. gondii) is an obligate intracellular parasite of the phylum  Apicomplexa1. It is estimated 
that one-third of the world’s population is infected with T. gondii. In most individuals, infection is asymptomatic 
and leads to chronic, life-long persistence of T. gondii-containing cysts, primarily in brain and muscle  tissue2. 
Active disease, also known as toxoplasmosis, usually occurs after reactivation of encysted parasites, and is often 
associated with immunosuppression. If untreated, toxoplasmosis may be fatal. Additionally, serious eye disease 
has been reported as a result of infection with T. gondii3 and, if a primary infection occurs during pregnancy, 
abortion, stillbirth and fetal abnormalities can  occur2,4. Whereas an acute infection is generally mediated by the 
fast-replicating tachyzoite stage of the parasite, the persistent tissue cysts, characteristic of a chronic infection, 
contain slow-replicating bradyzoites. Currently, treatment of toxoplasmosis is limited to the acute disease and 
requires prolonged exposure to anti-toxoplasmosis drugs for the duration of the  immunosuppression5,6.
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Containment of chronic T. gondii infection requires functional T-cell responses, in particular interferon 
gamma (IFN-γ)-producing  CD4+ T  cells2,7. In the absence of  CD4+ T cells, IFN-γ, its receptor or downstream 
effector molecules, such as inducible nitric oxide synthase (iNOS), susceptibility and disease are severely 
 exacerbated8–11. Accordingly, co-infection with human immunodeficiency virus (HIV), which impairs  CD4+ T 
cells during its reproduction, is one of the major reactivation factors. In fact, toxoplasmic encephalitis accom-
panied by low numbers of  CD4+ T cells is considered to be an AIDS-defining condition in  HIV+  individuals12.
In addition to antigen-specific  CD4+ T  cells11, innate immune cells, such as NK cells and neutrophils also 
contribute significantly to the production of host-protective IFN-γ13,14. In particular, the recognition of T. gondii-
derived profilin via Toll-like receptor (TLR)-11, which drives myeloid differentiation primary-response protein 
88 (MyD88)-dependent IL-12 secretion by dendritic cells, is considered a crucial upstream pathway of protective 
IFN-γ  secretion15,16. MyD88 or IL-12 knock-out mice are also susceptible to T. gondii  infection17,18. Furthermore, 
elegant studies by Hunter and colleagues showed that T cell-intrinsic ablation of MyD88 also impacts severely 
on the control of the  parasite19. These findings indicate that, in addition to IL-12, cytokine-driven IFN-γ secre-
tion in response to T. gondii also relies on IL-18, an IL-1 family cytokine originally known as IFN-γ-inducing 
factor, which requires cell-intrinsic MyD88  signaling20,21. IL-18 is particularly important for the rapid secretion 
of IFN-γ by cells of the immune system, in particular NK cells,  CD8+ memory T cells and double negative (DN) 
γδ T  cells22.
Proteolytic cleavage of IL-18 from biologically inactive pro-IL-18 requires caspase-123 and the activation of 
cytosolic inflammasome  sensors23. Deficiencies in caspase-1, IL-1824,25 and the inflammasome sensors NLRP1 
and  NLRP324,26 are associated with compromised immunity to T. gondi and several intracellular bacterial 
 pathogens27. Hence, the positive impact of targeting IL-18-mediated IFN-γ production on protective immunity 
has been demonstrated in models of Listeria monocytogenes, Mycobacterium tuberculosis and Salmonella enterica 
 infection28–30.
Given that control of acute toxoplasmosis depends on a delicate balance between limiting immunopathol-
ogy and maintaining parasite killing, in the present study, we interrogated the regulation of IL-18-driven IFN-γ 
production in vivo. We discovered that bioactive IL-18 is dependent on the sensing of viable parasites by multiple 
redundant inflammasome sensors in multiple hematopoietic cell types, leading to the hypothesis that enhance-
ment of this innate response could be harnessed to prevent disease resulting from infection with T. gondii. We 
therefore investigated if treatment with S4B6-containing IL2C, an IL2 complex that can boost NK and CD8+ T 
cell  numbers31, could prevent acute lethal toxoplasmosis.
Results
Toxoplasma‑driven IFN‑γ secretion by non‑CD4 immune cells following oral infection with 
brain cysts or intravenous (i.v.) infection with tachyzoites. Given that control of acute toxoplasmo-
sis critically depends on IFN-γ7 and non-CD4 immune cell types, such as  CD8+ T cells, DN T cells and NK cells, 
are prime IFN-γ producers, we wanted to delineate the mechanistic requirements of IFN-γ production by these 
cell types in response to T. gondii. We furthermore wanted to explore whether responses were similar after oral 
infection (a common natural route of infection), i.v. infection with tachyzoites (modelling blood transfusion, a 
rare but significant—for the individual—route of  infection32 and the often used purely experimental i.p. route of 
infection with tachyzoites.
We first inoculated naïve B6 mice with 10, 40 or 100 T. gondii ME49 cysts and assessed IFN-γ production by 
viable splenic  CD3+CD4+,  CD3+CD8+,  CD3+CD4–CD8– (DN) T cells and  CD3–NKp46+ cells 1 day and 5 days 
after inoculation. Whereas no IFN-γ production was observed 1 day after inoculation, a significant increase 
in IFN-γ-secreting cells was detected at 5 days after inoculation in spleen (Fig. 1a,b), mesenteric lymph nodes 
(MLN) (Fig. 1e,f) and Peyer’s Patches PP (Fig. S1a,b). Up to 10% of  CD8+ T cells and DN T Cells and up to 50% 
of all NK cells stained IFN-γ+, particularly following inoculation with 40 and 100 cysts.
We also investigated if rapid IFN-γ production could be induced by inoculation with tachyzoites via the i.v. 
and i.p. routes using a short-term in vivo exposure model in which naïve B6 mice were exposed to T. gondii 
tachyzoites for a maximum of 72 h. When mice were injected i.v. or i.p. with  105 tachyzoites, no significant IFN-γ 
production could be seen in either spleen, MLN or PP within 72 h (Fig. S1e). However, i.v. or i.p. inoculation 
with  107 tachyzoites led to secretion of IFN-γ by  CD3+CD8+,  CD3+CD4–CD8– (DN) T cells and  CD3–NKp46+ 
cells in spleen, MLN and PP as early as 2–24 h after inoculation (Fig. 1c,d, g, h; Fig. S1c,d), mirroring the results 
seen 5 days after a cyst inoculation (Fig. 1b,f). Importantly, at 24 h after tachyzoite inoculation, levels of other 
acute inflammatory mediators, such as IL-6, TNFα and IL-10, were almost indistinguishable from naïve mice 
(Fig. 1i–k), indicating that these cytokines were not impacting on protective IFN-γ responses 24 h after i.v. 
infection.
These results show that i.v., i.p. tachyzoite infections and oral brain cyst infections induce almost identical 
acute immune responses. Given that it is difficult to quantify the number of bradyzoites within brain cysts used 
for oral infection and, moreover, dissemination patterns following oral infection are erratic in individual  mice33, 
we subsequently focused on IFN-γ secretion 24 h after i.v. injection of tachyzoites as our primary readout for 
further dissection of the underlying mechanistic requirements.
Rapid IFN‑γ secretion in response to T. gondii requires IL‑12 and IL‑18. Whereas the role of IL-12 
in IFN-γ secretion is well established for T. gondii2, rapid production of IFN-γ in response to other intracel-
lular pathogens, such as S. enterica, L. monocytogenes and M. tuberculosis has also been linked to the upstream 
effects of IL-1828,29. To interrogate whether or not, and how early, IFN-γ secretion in response to T. gondii also 
requires IL-18, we exposed naïve B6 mice to T. gondii ME49 tachyzoites and treated the animals with neutraliz-
ing monoclonal antibodies (mAb) to IL-12, IL-18 or IL-12 and IL-18 immediately after inoculation. We focused 
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on NK cells for these and subsequent experiments, since this was the cell type for which the highest propor-
tion of cells stained positive for IFN-γ following inoculation with T. gondii (see Fig. 1). At 24 h after exposure, 
we assessed IFN-γ secretion by NK cells in the spleen ex vivo. Neutralization of IL-12 and IL-18 significantly 
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Figure 1.  Toxoplasma-driven IFN-γ secretion by non-CD4 immune cells following oral infection with 
brain cysts or intravenous (i.v.) infection with tachyzoites. (a,b) Percent of IFN-γ+ cells amongst total viable 
 CD3+CD4+,  CD3+CD8+,  CD3+CD4–CD8– (DN) T cells and  CD3–NKp46+ cells in the spleen 1 day (a) or 5 days 
(b) after B6 mice were inoculated orally with 10, 40 or 100 T. gondii ME49 brain cysts. (c) Percent of IFN-γ+ cells 
amongst total viable  CD3+CD4+,  CD3+CD8+,  CD3+CD4–CD8– (DN) T cells and  CD3–NKp46+ cells in the spleen 
2, 24, 48 or 72 h after B6 mice were injected i.v. with  107 T. gondii ME49 tachyzoites. (d) Percent of IFN-γ+ cells 
amongst total viable  CD3+CD4+,  CD3+CD8+,  CD3+CD4–CD8– (DN) T cells and  CD3–NKp46+ cells in the spleen 
24 h after B6 mice were injected i.p. with  107 T. gondii ME49 tachyzoites. (e,f) Percent of IFN-γ+ cells amongst 
total viable  CD3+CD4+,  CD3+CD8+,  CD3+CD4–CD8– (DN) T cells and  CD3–NKp46+ cells in mesenteric lymph 
nodes (MLN) 1 day (e) or 5 days (f) after B6 mice were inoculated orally with 10, 40 or 100 T. gondii ME49 
brain cysts. (g) Percent of IFN-γ+ cells amongst total viable  CD3+CD4+,  CD3+CD8+,  CD3+CD4–CD8– (DN) T 
cells and  CD3–NKp46+ cells in MLN 2, 24, 48 or 72 h after B6 mice were injected i.v. with  107 T. gondii ME49 
tachyzoites. (h) Percent of IFN-γ+ cells amongst total viable  CD3+CD4+,  CD3+CD8+,  CD3+CD4–CD8– (DN) T 
cells and  CD3–NKp46+ cells in MLN 24 h after B6 mice were injected i.p. with  107 T. gondii ME49 tachyzoites. 
(i–k) Serum concentrations of IL-6 (i), TNFα (j) and IL-10 (k) at 2–72 h after B6 mice were injected i.v. with 
 107 T. gondii ME49 tachyzoites. Results are presented as pooled data means ± SEM from at least two pooled 
independent experiments (n = 5–10 mice per group). See also Figure S1.
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the response (Fig. 2a). Consistent with this, where IL-12 levels in the serum of infected mice peaked at approxi-
mately 2 h after inoculation, the levels of IL-18 mirrored those of IFN-γ for up to 72 h (Fig. 2b). The significant 
reduction of rapid IFN-γ production in Il18–/– mice, and the almost complete absence of rapid IFN-γ produc-
tion in anti-IL-12-treated Il18–/– mice, further confirmed a direct correlation between IL-12, IL-18 and IFN-γ 
secretion (Fig. 2c,d). Furthermore, treatment with anti-IL-12 and/or anti-IL-18 also reduced concentrations of 
IFN-γ, IL-12 and IL-18 in the serum of infected mice in an additive manner (Fig. 2d–f). These results suggest 
a hierarchical relationship in which a primary IL-12-driven IFN-γ response is followed by an IL-18-dominant 
IFN-γ response. We concluded that innate IFN-γ secretion in response to T. gondii is driven by the secretion of 
IL-12 and IL-18.
IL‑18‑driven IFN‑γ secretion to T. gondii depends on multiple redundant inflammas-
omes. Given that the molecular mechanisms that lead to T. gondii-mediated IL-12 secretion are well 
characterized, we focused our attention on the host signaling pathways required for IL-18-driven IFN-γ pro-
duction, using a panel of genetically modified mouse strains. Secretion of bioactive IL-18 depends on the enzy-
matic cleavage of pro-IL-18 by caspase-123. Activation of caspase-1 involves the sensing of danger molecules 
or stress signals via upstream cytosolic PRRs, so called inflammasomes, a process that can be enhanced and 
controlled via TRIF-dependent caspase-11 activation. A significantly increased percentage of IFN-γ+ NK cells 
was seen in Caspase1/11–/– double KO mice, Nlrp1−/−mice, Nlrp3−/− mice and heterozygous Nlrp1+/−Nlrp3+/−, 
Nlrp1−/−Nlrp3+/− and Nlrp1+/−Nlrp3−/− mice infected with T. gondii versus uninfected mice, and this response 
could be almost completely prevented by additional anti-IL-12 treatment (Fig. 3a, Table S1). Caspase1/11–/– dou-
ble KO mice, Nlrp1−/−mice and Nlrp3−/− mice produced statistically significantly less IFN-γ following injection 
with T. gondii ME49 tachyzoites compared with B6 mice but, counter-intuitively, heterozygous Nlrp1+/−Nlrp3+/−, 
Nlrp1−/−Nlrp3+/− and Nlrp1+/−Nlrp3−/− mice did not; this may indicate a statistical rather than biological sig-
nificance to these particular data, the key observation being that all mice are capable of generating significant 
numbers of IFN-γ+ cells.
As expected, Caspase1/11–/– mice did not secrete significant levels of IL-18 following T. gondii inoculation 
(Fig. 3b), indicating that the remaining IFN-γ response in Caspase1/11–/– mice is driven by IL-12. Surpris-
ingly, when we tested mice deficient in the upstream NLR family pyrin domain-containing proteins 1 and 3 
(NLRP1 and NLRP3), NLR molecules that had been implicated previously in recognition of T. gondii24, both 
knockout strains secreted indistinguishable amounts of IL-18 compared with B6 mice (Fig. 3b; Table S2). This 
data suggested a redundant role for NLRP1 and NLRP3. However, even double knockout and heterozygous 
Nlrp1+/−Nlrp3+/−, Nlrp1−/−Nlrp3+/− and Nlrp1+/−Nlrp3−/− mice secreted high levels of IL-18 after exposure to T. 
gondii ME49 tachyzoites (Fig. 3b; Table S2), suggesting that additional PRR molecules must be involved in sensing 
of T. gondii invasion in vivo. Taken together these results indicate that rapid IFN-γ secretion in vivo in response 
to T. gondii depends on the inflammasome → caspase-1→ IL-18 axis, and that T. gondii likely activates at least 
three different inflammasomes in vivo.
Toxoplasma gondii activates inflammasomes in multiple cell types. To further investigate the role 
of cytosolic PRRs in sensing T. gondii invasion, and to potentially target inflammasome activation for preven-
tive or therapeutic intervention strategies, we next tried to identify the T. gondii-sensing cell type in vivo. To do 
this, we made use of a red fluorescent protein (RFP) tagged T. gondii ME49 (T. gondii ME49-RFP) strain to track 
parasite uptake by different immune cell subsets in the spleen. Twenty-four hours after tachyzoite injection, T. 
gondii ME49-RFP also induced rapid IFN-γ secretion by splenic  CD3+CD4+,  CD3+CD8+,  CD3+CD4–CD8– (DN) 
T cells and  CD3–NKp46+ cells (Fig. 4a) and high levels of serum IL-18 (Fig. 4b), similar to wild-type T. gondii 
ME49 (see Figs. 1 and 2). Approximately 0.5% of all splenocytes contained T. gondii ME49-RFP in vivo 24 h 
after inoculation (Fig. 4c). Sorted  RFP+ cells secreted significantly more IL-18 ex vivo compared to  RFP− cells 
(Fig. 4d), and further surface phenotyping revealed that T. gondii ME49-RFP was primarily contained in mono-
cytes, neutrophils and CD8α+ dendritic cells (Fig. 4e,f). Splenic MHC-II+CD11c+ DCs,  CD11b+Ly6G+ neutro-
phils and  CD11b+Ly6C+ monocytes each comprised approximately 20–30% of all RFP-containing cells after i.v. 
tachyzoite injection. Only very few T cells, B cells and macrophages appeared to harbor parasites (Fig. 4e,f). 
To investigate if cell types that contained T. gondii ME49-RFP parasites also activated inflammasomes, we per-
formed intracellular staining for the inflammasome adaptor molecule apoptosis-associated speck-like protein 
containing a carboxy-terminal CARD (ASC), and measured the activation of caspase-1 with a fluorescent inhibi-
tor that only binds to activated caspase-1 (FLICA FAM-YVAD-FMK)29. Consistent with the uptake of T. gondii 
ME49-RFP by different cell types, T. gondii ME49-RFP parasite-harboring neutrophils, monocytes and DCs also 
expressed higher levels of ASC and FAM-YVAD compared with  RFP− cells and FMO controls (Fig. 4g). Col-
lectively, these results indicate that T. gondii infection activates multiple redundant inflammasomes in multiple 
different hematopoietic cell-types in vivo.
IL‑18‑driven IFN‑γ secretion to T. gondii depends on viable parasites but is independent of 
secreted GRA proteins. Next, we assessed if rapid IFN-γ secretion in response to T. gondii required viable 
parasites or could be induced by soluble factors. To this end, naïve B6 mice were injected with either live, heat-
killed or sonicated T. gondii ME49 tachyzoites. Inoculation with live parasites induced significantly increased 
IFN-γ secretion by NK cells and increased serum IL-18 levels compared to heat-killed or sonicated parasites 
(Fig. 5a,b). To exclude the possibility that heat inactivation and sonication destroyed soluble factors that could 
potentially drive this response, we also injected naïve B6 mice with HFF cell debris, which had been re-sus-
pended in the T. gondii ME49 culture supernatant. This treatment also failed to induce IFN-γ and IL-18 secretion 
(Fig. 5a,b). These results indicated that viable parasites are required to initiate an IFN-γ response, suggesting that 
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T. gondii virulence factors may play a critical role. Evidence from studies that have investigated the mechanistic 
framework of how intracellular bacterial pathogens activate inflammasomes in vivo, suggests that secreted effec-
tor molecules and/or distinct structural proteins are critically  required34. Apicomplexan parasites also secrete 






















































































































































































Figure 2.  Rapid IFN-γ production in response to T. gondii requires IL-12 and IL-18. (a) Percent of IFN-γ+ 
cells amongst total viable  CD3–NKp46+ cells in the spleen 24 h after B6 mice were injected i.v. with  107 T. gondii 
ME49 tachyzoites. Some mice received an i.p. injection of 200 µg mAb against IL-18 and/or IL-12 immediately 
after injection of T. gondii. (b) Serum concentrations of IL-18, IL-12p70 and IFN-γ at various time points 
after B6 mice were injected i.v. with  107 T. gondii ME49 tachyzoites. (c) Percent of IFN-γ+ cells amongst total 
viable  CD3–NKp46+ cells in the spleen 24 h after B6 or Il18−/− mice were injected i.v. with  107 T. gondii ME49 
tachyzoites. Some mice received an i.p. injection of 200 µg mAb against IL-12 immediately after injection of T. 
gondii. (d) Serum concentrations of IL-18 24 h after B6 or Il18−/− mice were injected i.v. with  107 T. gondii ME49 
tachyzoites. Some mice received an i.p. injection of 200 µg mAb against IL-12 immediately after injection of 
T. gondii. (e) Serum concentrations of IFN-γ 24 h after B6 or Il18−/− mice were injected i.v. with  107 T. gondii 
ME49 tachyzoites. Some mice received an i.p. injection of 200 µg mAb against IL-18 and/or IL-12 immediately 
after injection of T. gondii. (f) Serum concentrations of IL-12 24 h after B6 or Il18−/− mice were injected i.v. 
with  107 T. gondii ME49 tachyzoites. Some mice received an i.p. injection of 200 µg mAb against IL-18 and/
or IL-12 immediately after injection of T. gondii. Results are presented as individual data points (a,c,d,e,f) or as 
means ± SEM (b) of 4–15 mice per group from at least two pooled independent experiments. Statistical analyses: 
One-way ANOVA followed by Dunnett’s multiple comparison test. Significant differences are indicated by 
asterisks: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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effector molecules with distinct host-modulatory  properties35. In particular, dense granule (GRA) proteins have 
been shown to play important roles in the maintenance of the parasitophorous vacuole (PCV), for the intracellu-
lar lifestyle and to exert host-modulatory  functions36. We further probed the parasite-derived factors that might 
drive early, IL-18-dependent IFN-γ secretion by exposing naïve B6 mice to a panel of T. gondii strains to test if 
GRA proteins are required for IL-18-driven IFN-γ secretion. Hence, we infected mice with a mutant strain of 
T. gondii ME49 that lacks ASP5, a critical requirement for secretion of GRA  proteins37, as well as strains lacking 
GRA20 or GRA23, two proteins that contain the PEXEL motif required for PCV exit. No significant difference 
in the levels of serum IL-18 and NK cell-produced IFN-γ was observed 24 and 48 h after inoculation with T. 
gondii ME49 ASP5-deficient tachyzoites compared with inoculation of a wildtype T. gondii ME49 (Fig. 5c,d), 
suggesting that ASP5-driven GRA export is dispensable for inflammasome activation. Similarly, inoculation 
with GRA20-deficient or GRA23-deficient parasites did not significantly reduce IFN-γ secretion in the absence 
of IL-12 (Fig. S2). We also tested another Type II T. gondii isolate, DEG (T. gondii DEG), which had been impli-
cated in reduced IL-1β secretion following in vitro infection of  macrophages24 but, similar to inoculation with 
T. gondii ME49 ASP5-deficient parasites, inoculation with T. gondii DEG did not lead to reduced levels of serum 
IL-18 and NK cell-produced IFN-γ in this model (Fig. 5c,d). At 48 h after DEG tachyzoite inoculation, the levels 
of serum IL-18 were, if anything, slightly higher compared with inoculation of T. gondii ME49, though this was 
not statistically significant (Fig. 5d). These data indicate that ASP5-dependent secretion of GRA proteins does 
not affect IL-18-driven IFN-γ secretion in vivo and highlights the diverging mechanisms that underlie in vitro 
IL-1β and in vivo IL-18 secretion in response to T. gondii.
IL2C treatment expands IL‑18‑responsive IFN‑γ‑secreting cell subsets. Collectively, the results 
presented so far raise the prospect that, if the ability of non-CD4 cells to invoke inflammasome-dependent, IL18-
driven production of IFN-γ can be enhanced, it may be possible to control acute toxoplasmosis in AIDS. Hence, 
we investigated if targeted expansion of non-CD4 cells with IL2C treatment can achieve this. First, naïve mice 
were treated i.p. with IL2C complex on four consecutive days (Fig. 6a) and, 24 h after the last IL2C injection, 
immune cell expansion was assessed by flow cytometry relative to untreated animals. As reported  previously38, 
IL2C treatment led to a significant expansion of memory  CD8+ T cells, NK cells and DN T cells in spleen and 
MLN (Fig. 6b,c) though increases observed in the PP were not statistically significant (Fig. 6d). Next we assessed 
if IL2C-expanded and non-expanded  CD8+ T cells, DN T cells and NK cells responded similarly to T. gondii 
infection. IL2C-treated and untreated mice were infected with  107 ME49 tachyzoites for 24  h (Fig.  6a). The 
percentage of  CD8+ T cells, DN T cells and NK cells producing IFN-γ was almost indistinguishable between 
IL2C-treated and untreated mice (Fig. 6e). The number of IFN-γ+ NK cells, IFN-γ+  CD8+ T cells and IFN-γ+ 
DN T cells increased 3–30 fold following IL2C treatment (Fig. 6f). Similarly, IL2C pretreatment significantly 
increased systemic IFN-γ levels in the serum after i.v. infection (Fig.  6g) but, as expected, did not lead to a 
significant change in the levels of serum IL-18 (Fig. 6h). We also assessed the expression of IL18R and IL12R 
on the surface of IFN-γ+ and IFN-γ− cells. IFN-γ+ NK cells (data for  CD8+ T cells and DN T cells not shown) 
expressed significantly higher levels of IL18R and IL12R compared to IFN-γ− NK cells (Fig. 6i,j). Taken together, 



























































































Figure 3.  IL-18-driven IFN-γ secretion to T. gondii depends on multiple redundant inflammasomes. (a) 
Percent of IFN-γ+ cells amongst total  CD3–NKp46+ cells in the spleen 24 h after i.v. injection of  107 T. gondii 
ME49 tachyzoites into B6 mice and different mouse strains lacking either Caspase1/11, Nlrp1, Nlrp3 or Nlrp1 
and Nlrp3. (b) Serum IL-18 concentrations 24 h after i.v. injection of  107 T. gondii ME49 tachyzoites into B6 
mice and different mouse strains lacking either Caspase1/11, Nlrp1, Nlrp3 or Nlrp1 and Nlrp3. Results are 
presented as individual data points of 3–25 mice per group from at least two pooled independent experiments. 
Statistical analyses: Two-way ANOVA followed by Tukey’s post hoc test. Significant differences within each 
mouse genotype are indicated by asterisks: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; n.s. not significant. 
Further significance values are shown in Tables S1 and S2.
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treatment is to numerically expand IFN-γ producing cells that maintain higher IL-18R and IL-12R levels of 
expression compared to IFN-γ− cells.
IL2C pre‑treatment protects mice from acute lethal toxoplasmosis independently of  TReg 
expansion and parasite burden. To definitively assess if IL2C-mediated expansion of IL-18-responsive 
IFN-γ-secreting non-CD4 cell subsets can prevent lethal toxoplasmosis in mice, we used the well-established 
oral inoculation model with T. gondii ME49 bradyzoite-containing brain cysts. As above, naïve B6 mice were 
treated i.p. with IL2C for four consecutive days (Fig. 7a). IL2C treatment was accompanied by a weight loss from 
which mice recovered within a few days (data not shown). Forty-eight hours after the last IL2C treatment, mice 
were inoculated orally with 10 or 40 T. gondii ME49 cysts and were assessed for weight loss and consequent sur-
vival, whereby mice were euthanized when weight loss exceeded 20% of body weight, in accordance with Animal 
Ethics Committee of James Cook University Approvals A2138 and A2324. All mice that had been inoculated 
with 40 cysts and 87% of mice that had been inoculated with 10 cysts, but had not received IL2C injections, suc-
cumbed within 14 days after inoculation (Fig. 7b,c). In contrast, IL2C pre-treatment extended survival in mice 
that had been inoculated with 40 cysts up to 36 days, and approximately 40% of mice that had been inoculated 
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Figure 4.  T. gondii activates inflammasomes in multiple cell types. (a) Percent of IFN-γ+ cells amongst total 
viable splenic  CD3+CD4+,  CD3+CD8+,  CD3+CD4–CD8– (DN) T cells and  CD3–NKp46+ cells in naïve mice 
24 h after i.v. injection of  107 T. gondii ME49-RFP tachyzoites. (b) Serum IL-18 levels in naïve mice 24 h after 
i.v. injection of  107 T. gondii ME49-RFP tachyzoites. (c) Representative FACS plots showing total viable splenic 
 RFP+ cells 24 h after i.v. injection of  107 T. gondii ME49-RFP tachyzoites. (d) IL-18 levels in supernatant of 
sorted  RFP+ and  RFP− cells after incubation at 37 °C for 24 h. (e) Representative FACS plots showing gated 
 RFP+ neutrophils. Monocytes, macrophages, dendritic cells (DCs) and T/B cells 24 h after i.v. injection of  107 T. 
gondii ME49-RFP tachyzoites. (f) Enumeration of  RFP+ cell types shown in (e). (g) Representative histograms 
of cell type-specific gated  RFP+ and  RFP− cells showing expression levels of ASC (left panels) or FAM-YVAD 
(right panels) 24 h after i.v. injection with  107 T. gondii ME49-RFP tachyzoites. FMO control for ASC panels 
are cells from infected animals that did not get stained with anti-ASC-Alexa488 but all other antibodies. FMO 
control for FAM-YVAD are cells from mice that were injected with T. gondii ME49-RFP but did not receive an 
injection with FLICA FAM-YVAD. MFI values ± SD for FAM-YVAD expression in  RFP+ and  RFP− neutrophils, 
monocytes and DCs from three mice shown in table. Results are presented as individual data points (d,f), 
pooled data means ± SEM (a,b) and representative FACS plots (c,e) and histograms (g) of 6–9 mice from 
two or three pooled independent experiments. Statistical analyses: One-way ANOVA followed by Dunnett’s 
multiple comparison test (a) or Student’s t-test (b,d,g); significant differences are indicated by asterisks: *p < 0.05; 
**p < 0.01; ***p < 0.001.
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Importantly, depletion of NK cells,  CD8+ T cells, Thy1.2+ cells (expressed on all T cells and immature NK 
 cells39 or IFN-γ from mice that had been treated with IL2C for four days and had been inoculated with 10 T. 
gondii ME49 cysts with neutralizing antibodies reversed IL2C-mediated increase in survival (Fig. 7d,e), indicat-
ing that IL2C-mediated cell expansion directly correlated with increased survival. Similarly, neutralization of 
IL-18, IL-12 or IFN-γ, reversed the protective phenotype (Fig. 7d,f). All mice that were not treated with IL2C 
succumbed to the infection by day 16, with a median survival of 11 days (Fig. 7f). Whilst 67% of IL2C-treated 
mice that received control rat IgG survived until day 60, the median survival for mice treated with anti-IFN-γ 
was 10.5 days, 13 days for mice treated with anti-IL-12 and 14 days for mice treated with anti-IL-18 (Fig. 7f). 
All mice that survived until day 60 were assessed for T. gondii brain cysts and all contained cysts in their brain, 
indicating that all mice were infected and that survival was not due to a failure of the infection to establish.
To assess if IL2C pre-treatment also impacts on measurable disease parameters other than survival, we also 
assessed pathology, parasite burden, serum cytokine levels and  TReg numbers in MLN and lamina propria (LP) 
at 2, 4 and 9 days following oral cyst infection. At 9 days after infection, IL2C pre-treated mice displayed signifi-
cantly reduced gross pathology of gut and liver (Fig. 7g,h) in the absence of any effect on parasite burden (Fig. 7i); 
thus, parasite burden was below detection limits in IL2C-treated and untreated animals at 2 days after infection 
and progressively increased at the same rate in both groups through days 4 and 9 post-infection (Fig. 7i). Due 
to the low infectious dose of 10 cysts, inflammatory cytokines such as IFN- γ, IL-6, IL-12 and TNF were not 
detectable in any mice at 2 and 4 days after infection and, although detectable at day 9 post-infection, there was 
no significant difference in the levels of these cytokines in IL2C-treated versus untreated mice (data not shown). 
Similarly, systemic IL-10 levels (Fig. 7j) and  TReg numbers in MLN and lamina propria were not increased by 
IL2C injections (Fig. 7k–m) suggesting a role for IL2C pre-treatment independent of the previously reported 
 TReg expansion with JES6-1A12-containing  IL2C40,41. Collectively, these results demonstrate a protective role of 
IL2C pre-treatment in acute lethal murine toxoplasmosis that is dependent on IL-12, IL-18 and IFN-γ but is 
independent from effects on parasite burden.
Discussion
Non-CD4 cells, such as  CD8+ T cells, DN T cells and NK cells, have been implicated in early control of severe 
infections with intracellular pathogens, including T. gondii, M. tuberculosis and Salmonella2,29. Our study pro-
vides a mechanistic framework for how T. gondii activates IFN-γ secretion by protective  CD8+ T cells, DN T 
cells and NK cells. In particular, we demonstrate that in vivo IL-18-driven IFN-γ secretion in response to T. 
gondii likely requires the activation of at least three different inflammasomes. The involvement of both NLRP1 
and NLRP3 has been shown in other, distinct models of  toxoplasmosis24 but, in the model presented here, only 
Caspase1/11−/− mice but not Nlrp1−/−, Nlrp3−/− and Nlrp1±/−Nlrp3±/− mice were devoid of circulating IL-18 after 
T. gondii infection. These results suggest that a third sensor for in vivo T. gondii detection must exist in addition 
to NLRP1 and  NLRP324,42. This conclusion is underscored by the fact that Caspase1/11−/− mice but not Nlrp1−/−, 








































































































































Figure 5.  IL-18 driven IFN-γ secretion to T. gondii depends on parasite viability but is independent of secreted 
GRA proteins. (a) Percent of IFN-γ+ cells amongst total viable splenic  CD3–NKp46+ cells in naïve mice 24 h after 
i.v. injection of live  107 T. gondii ME49, heat-killed or sonicated ME49 tachyzoites, or HFF debris with culture 
supernatant. (b) Serum IL-18 levels in naïve mice 24 h after i.v. injection of live  107 T. gondii ME49 heat-killed 
or sonicated ME49 tachyzoites, or HFF debris with culture supernatant. (c) Percent of IFN-γ+ cells amongst total 
viable splenic  CD3–NKp46+ cells in naïve mice 24 and 48 h after i.v. injection of live  107 T. gondii ME49, DEG 
or ME49ΔASP5 tachyzoites.(d) Serum IL-18 levels in naïve mice 24 and 48 h after i.v. injection of live  107 T. 
gondii ME49, DEG or ME49ΔASP5 tachyzoites. Results are presented as individual data points of 4–15 mice per 
group from at least two pooled independent experiments. Statistical analyses: One-way ANOVA per time-point 
followed by Dunnett’s multiple comparison test; significant differences are indicated by asterisks: ***p < 0.001; 
****p < 0.0001; n.s. not significant. See also Figure S2.
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with T. gondii. Furthermore, we show that inflammasome activation occurred in CD8α+ DCs, inflammatory 
monocytes and neutrophils, cell types that have also been implicated in IL-12 secretion in response to T. gondii2. 
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Figure 6.  IL2C treatment expands IL-18-responsive IFN-γ-secreting cell subsets. (a) Experimental plan 
showing that naïve B6 mice were treated i.p. with IL2C on four consecutive days. One day after the last 
administration, some mice were euthanized to isolate cells from spleens, mesenteric lymph nodes (MLN) and 
Peyer’s Patches (PP). Other mice were injected i.v. with  107 T. gondii ME49 tachyzoites 2 days after the last IL2C 
treatment mice and cells were isolated 24 h later. (b–d) Numbers of  CD3+CD8+,  CD3+CD4–CD8– (DN) and 
 CD3−NKp46+ cells (enumerated by FACS) in spleens (b), MLN (c) and PP (d) of naïve B6 mice that were treated 
i.p. with IL2C on four consecutive days and euthanased 1 day after the last administration. (e,f) Proportions 
(e) and total numbers (f) of  CD3–NKp46+  CD3+CD4+,  CD3+CD8+ and  CD3+CD4–CD8– (DN) IFN-γ+ cells 
(assessed by FACS) in spleens of B6 mice that were treated i.p. with IL2C on four consecutive days and, 2 days 
after the last IL2C treatment, were injected i.v. with  107 T. gondii ME49 tachyzoites and cells isolated 1 day 
later. (g,h) IFN-γ (g) and IL-18 (h) serum concentrations of B6 mice that were treated i.p. with IL2C on four 
consecutive days and, 2 days after the last IL2C treatment, were injected i.v. with  107 T. gondii ME49 tachyzoites, 
and serum collected 1 day later. (i,j) Expression of IL18R (i) and IL12R (j) on IFN-γ− (blue histogram) and IFN-
γ+  CD3–NKp46+ cells after i.v. infection with  107 T. gondii ME49 tachyzoites with (orange histogram) or without 
(red histogram) IL2C treatment. Results are presented as pooled data means ± SEM from at least two pooled 
independent experiments with 5–6 mice per group (b,c,d,e,f), with individual data points shown for (g,h), 
and as representative histograms and individual data points of mean fluorescent intensity for (i,j). Statistical 
analyses: One-way ANOVA followed by Dunnett’s multiple comparison test (a,b,c,d,e,f); significant differences 
are indicated by asterisks: * p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; n.s. not significant.
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inflammasome signaling pathway. This is in contrast to the often very specific recognition of viral and bacterial 
infections by one particular inflammasome in a distinct cell  type28,29,43–46. It is likely that this divergence highlights 
the evolutionary complexity of parasites and suggests that more highly evolved organisms have developed a more 
complex inflammasome-dependent interplay with their hosts. In line with this hypothesis, it was shown recently 
in vitro that T. gondii also activates the NLRC4 and AIM2 inflammasomes in human fetal small epithelial  cells47, 
as well as the expression of NLRP6, NLRP8 and NLRP13 in THP-1  macrophages48. Given that myeloid cell sub-
sets often express distinct arsenals of PRRs on the cell surface and intracellularly, their ability to recognize and 
interact with T. gondii differs. Subsequently, the identification and characterization of distinct myeloid cell types 
producing IL-18 in response to T. gondii may foster innovative strategies for targeted interventions.
Toxoplasma gondii appears to activate both NLRP1 and  NLRP324, yet the specificity of this activation remains 
elusive. While NLRP3 activation in response to T. gondii is influenced by  P2X7 receptor-dependent potassium 
efflux and the induction of reactive oxygen  species47,49–51, the exact mechanisms of how T. gondii activates multiple 
inflammasomes remain enigmatic. It is also interesting to note that in vitro infection of mouse macrophages and 
human monocytes with T. gondii only leads to the secretion of IL-1β, but not IL-1824,52. In contrast, in vivo infec-
tion in mice leads to significant secretion of IL-18 but not IL-1β24. It has even been suggested that in vitro infec-
tion of human neutrophils leads to evasion of NLRP3 activation and IL-1β  secretion53. Furthermore, in vitro acti-
vation of inflammasomes differs between T. gondii strains, and is predominantly induced by Type II  parasites24. 
These findings suggest that T. gondii has evolved sophisticated diverging effector mechanisms to manipulate 
inflammasome biology in different host cell subsets, and suggest that secreted effector molecules and/or distinct 
structural proteins may underlie inflammasome activation. It is, therefore, interesting that Nlrp1±/−Nlrp3±/− mice 
did not show reduced IL-18 secretion after infection with T. gondii. It is important to note that in mice the Nlrp1 
locus is on the same chromosome as the Nlrp3 gene, meaning that the generation of rare double knockout off-
spring relies on recombination rather than inheritance. It will therefore be important to further investigate the 
role of Nlrp1 and 3 with alternative methods, such as CRISPR/Cas9 and/or chemical inhibition.
Our study has ruled out ASP5-dependent GRA  proteins37, the most abundant family of T. gondii-derived effec-
tor  molecules35, as the primary activator of inflammasomes. GRA molecules influence several host cell  pathways54 
and are required for the transport of small molecules across the parasitophorous  vacuole55. These results do not 
exclude GRA proteins that don’t depend on ASP5 for export, and further studies will have to investigate the 
role of ASP5-independent GRA proteins as well as rhoptry proteins and other surface structures in driving this 
process. In particular, the recently described MYR1 protein export  system56–58 may be valuable in answering if 
secreted effector molecules are at all required to initiate inflammasome activation.
It is tempting to speculate that the overall purpose of activating multiple inflammasomes in multiple cell 
types is to drive an inflammatory host response that mediates the progression of T. gondii into the chronic cyst 
phase, while at the same time preventing activation of parasite- killing mechanisms. Toxoplasma can invade and 
replicate in virtually all nucleated cell types of warm-blooded animals. From an evolutionary perspective, it is not 
surprising that the arms race between the host and the parasite has led to the evolution of numerous strategies to 
activate the immune system (from the parasite’s perspective) and to sense the invasion (from the host’s perspec-
tive). The fundamental differences between the habitats and the composition of the immune system of susceptible 
warm-blooded host species may require T. gondii to activate as many different inflammasome sensors as possible. 
It is well established that T. gondii requires a pro-inflammatory, IFN-γ-dominated immune response to form 
 cysts7. Because transmission is critical for the parasite’s survival and completion of the life cycle, it is maladap-
tive for T. gondii to kill its host. This may explain why IFN-γ neutralization is fatal, because IFN-γ deficiency 
favors tachyzoite replication and prevents cyst formation. Furthermore, these findings may also explain why T. 
gondii cysts reactivate after HIV co-infection in humans; HIV destroys  CD4+ T cells, a prime IFN-γ producer. 
Hence, we reasoned that a viable adjunct therapy in T. gondii/ HIV co-infection might be achieved by boosting 
IFN-γ-producing NK cells,  CD8+ T cells and DN T cells to prevent acute toxoplasmosis.
Figure 7.  IL2C pre-treatment protects mice from acute, lethal toxoplasmosis independently of  TReg expansion 
and parasite burden. (a) Experimental plan showing that naïve B6 mice were treated i.p. with IL2C on four 
consecutive days or left untreated. Two days after the last IL2C treatment, mice were inoculated orally with 
10 or 40 T. gondii ME49 brain cysts and survival was assessed over time. (b,c) Percent survival of B6 mice, 
untreated or treated with IL2C before being inoculated orally with 40 (b) or 10 (c) T. gondii ME49 brain cysts. 
(d) Experimental plan showing that naïve B6 mice were treated as described in (a) with IL2C-treated animals 
receiving weekly i.p. injections with mAb and survival being assessed over time. (e,f) Percent survival of B6 
mice, inoculated orally with 10 T. gondii ME49 brain cysts, untreated or treated with IL2C and mAb against 
IFN-γ, CD8, NK1.1, Thy1.2 or control rIgG (e), or with mAb against IL-12, IL-18, IFN-γ or control rIgG (f). 
(g,h) Gross pathology of the intestines (g) or livers (h) and parasite burden in the spleen (i) and IL-10 levels in 
the serum (j) of B6 mice, untreated or treated with IL2C, 2, 4 and/or 9 days after being inoculated orally with 
10 T. gondii ME49 brain cysts. (k) Representative FACS plots of  CD3+CD4+CD25+Foxp3+ regulatory T cells 
from MLN and lamina propria (LP) of B6 mice, untreated or treated with IL2C, 2 days after being inoculated 
orally with 10 T. gondii ME49 brain cysts. (l,m) Numbers of regulatory T cells from MLN (l) and LP (m) of B6 
mice, untreated or treated with IL2C, 2, 4 or 9 days after being inoculated orally with 10 T. gondii ME49 brain 
cysts. Results are presented as individual data points (g,h,i), pooled data means (b,c,e,f,j,l,m) or representative 
FACS plots (k) from two to three pooled independent experiments with 5–15 mice per group. Statistical 
analyses: One-way ANOVA followed by Dunnett’s multiple comparison test (g,h,l,m), Student’s t-test (i) or 
Log-rank (Mantel–Cox) test (b,c,e,f); significant differences are indicated by asterisks: *p < 0.05; **p < 0.01; 
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Interleukin-2 and Interleukin-15 are critical cytokines for the maturation and survival of IL-18 responsive DN 
T cells, NK cells and  CD8+ T  cells59–64. The role of IL-15 in immunity to T. gondii remains  controversial65,66, but 
IL-2 knockout mice are highly susceptible to T. gondii  infection67, and injection of recombinant IL-2 enhances 
survival of Toxoplasma-infected  mice68,69. Because IL-2 and IL-15 signaling depends on trans-presentation70,71, 
complexing IL-2 with anti-IL-2 (IL2C) or IL-15 with IL-15RαFc (IL15C) significantly enhances their biological 
activity in vivo31,72. Importantly, the binding site of the anti-IL2 clone used in the IL2C determines whether a 
preferential expansion of regulatory T cells  (TReg; anti-IL-2 clone JES6-1A12) or  CD8+ T cell, NK cells and DN 
T cells occurs (anti-IL-2 clone S4B6)31,73.
Using JES6-1A12-containing IL2C, Akbar et al.41 showed that selective expansion of  TReg cells in Type I T. 
gondii RH-infected animals improved control of the parasite. It was also demonstrated that  TReg expansion with 
JES6-1A12-containing IL2C can overcome the competition for bioavailable IL-2 by regulatory and effector T 
cells, leading to reduced immunopathology and morbidity during acute Type II T. gondii ME49  infection40. 
These studies are in line with other reports showing a collapse of  TReg cells during acute T. gondii infection due 
to IL-2 starvation and an overall protective role of  TRegs in acute T. gondii-mediated  immunopathogenesis74–77. 
In contrast to JES6-1A12-containing IL2C, S4B6-containing IL2C has been shown to boost NK cell and memory 
 CD8+ T cell numbers in mice and to enhance their cytolytic capacity against viral infections,  malaria78 and cancer 
 cells70,79–81. Short-term exposure of naïve mice to IL2C containing S4B6 has also been shown to enhance resist-
ance and immunity against Listeria monocytogenes  infection82. Our study is the first to show a protective effect 
of S4B6-containing IL2C pre-treatment in toxoplasmosis and our results suggest that IL2C pre-treatment can 
protect mice from lethal toxoplasmosis via distinct mechanisms, depending on the IL-2 mAb clone used to pre-
pare the cytokine complex. Thus, JES6-1A12-containing IL2C seems to compensate for the limited bioavailability 
of IL-2 for Treg survival during acute T. gondii infection, leading to reduced immunopathology, whereas S4B6-
containing IL2C, whilst also reducing pathology without affecting parasite burden, does so in a Treg-independent 
manner. Our findings do not definitively rule out a role for Treg function or local (i.e., gut) IL-10 in SB46 IL2C 
treated mice (e.g., via use of Treg ot IL-10 depleted or knockout mice) but our results do show that S4B6 IL2C 
treatment has no effect on systemic IL-10 levels, further pointing towards a Treg-independent function. Based 
on our results, we conclude that S4B6-containing IL2C seems to favor survival and expansion of IL-18-driven 
IFN-γ secretion, possibly driving parasites towards stage conversion and cyst formation. It is, hence, tempting 
to speculate that both types of IL2C could have a synergistic effect if applied together.
Cytokine complex-mediated immunotherapy has not only attracted attention in models of infectious dis-
eases but also in the cancer  field83. IL2C treatment reduces viral load in a mouse model of gamma-herpesvirus 
 infection84 and impacts positively on mouse  melanoma85 and BCL1  leukemia86. More recently, IL2C treatment 
has also been tested successfully in cancer models in combination with immune checkpoint  blockade87. IL-15/
IL-15Rα-Fc complexes (IL15C) have also been shown to expand  CD8+ T cell, DN T cell and NK cell populations, 
and to protect mice against cerebral malaria via the induction of IL-10-producing NK  cells78. Whether IL15C 
would also be protective in our model of lethal toxoplasmosis remains to be investigated. Taken together, these 
results suggest that cytokine complex treatment may be a more broadly applicable adjunct therapy in infec-
tious diseases, but also highlight that the protective mechanisms may differ between different pathogens and 
cytokine complex types used. To our knowledge, no data are available yet on any clinical use of IL2C and IL15C 
in humans. It will be important to consider the hyper-inflammatory response that can be attributed to IL2C and 
IL15C treatment and, hence, careful consideration should be taken before using cytokine complexes clinically 
in the context of toxoplasmosis.
In summary, here we delineate a mechanistic framework for how IFN-γ is produced by non-CD4 cell types 
in vivo in response to T. gondii, including a crucial role for parasite viability and inflammasome-dependent 
IL-18 secretion. Our results demonstrate that in vivo inflammasome activation in response to T. gondii occurs 
in multiple myeloid cell types and indicate the existence of an unidentified T. gondii-sensing component. Addi-
tionally, our study excludes T. gondii-derived, ASP5-dependent, dense granule proteins as the main activators of 
inflammasomes in vivo. The observation that both IL-12 and IL-18 neutralization reverses the host protective role 
of  CD8+ T cells, DN T cells and NK cell-produced IFN-γ during T. gondii infection highlights the redundancy 
and functional interchangeability of both cytokines during T. gondii infection. This combination of observations 
led us to the hypothesis that enhancement of inflammasome-dependent, IL18-driven production of IFN-γ by 
non-CD4 cells may be a route to control acute toxoplasmosis in AIDS. In accord with this, we provide compel-
ling evidence for a protective role of IL2C pre-treatment in lethal toxoplasmosis. We demonstrate that IL2C-
mediated expansion of  CD8+ T cells, NK cells and DN T cells protects mice against acute disease and death in 
an IFN-γ-dependent manner. Hence, we conclude that inducing immune responses that lead to the expansion 
of IFN-γ-secreting  CD8+ T cells, DN T cells and NK cells could be a crucial feature of improved toxoplasmosis 
intervention strategies, perhaps most particularly in the context of HIV co-infection and AIDS.
Methods
Mice. C57BL/6  J and Arc(S) mice were purchased from the Animal Resource Center (Perth, Australia). 
Knockout mice (Caspase1/11–/–, Nlrp1−/−, Nlrp3–/– and Il18−/−) were bred and maintained at the Australian 
Institute of Tropical Health and Medicine, James Cook University, Cairns and Townsville, Australia. Double 
knockout mice (Nlrp1−/−Nlrp3−/−) mice were bred by sequentially crossing Nlrp1−/−88 and Nlrp3−/− mice. Geno-
typing was performed using the following primer pairs: Nlrp3-F 5′-GCT CAG GAC ATA CGT CTG GA-3′,Nlrp3-R 
5′-TGA GGT CCA CAT CTT CAA GG-3′,Nlrp3-R2 5′-TTG TAG TTG CCG TCG TCG TCCTT-3′,Nlrp1 WT: Nal-
p1aF 5′-TGG AAG GAA GGC AAG CTT TA-3′; Nalp1aR 5′-ACC CAG GGA ACT TCA CAC AG-3′; Nlrp1 mutant: 
Nalp1aF 5′-TTT AGA GCT TGA CGG GGA AA-3′; Nalp1aR 5′-GGA AGG ACT TCC CAC CCT AA-3′. The follow-
ing mice were used for experiments: Nlrp1−/−Nlrp3−/−, Nlrp1+/−Nlrp3−/− and Nlrp1−/−Nlrp3+/−. For infection 
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experiments, all mice were sex- and age-matched, and kept in our BSL 2 animal facility under specific pathogen-
free (SPF) conditions.
Parasites. Type II T. gondii strains ME49, ME49-RFP, ME49 GRA20-deficient, ME49 GRA23-deficient, 
ME49 ASP5-deficient and DEG (ATCC, ATC50855) were maintained by continuous passage in human foreskin 
fibroblasts (HFF; ATCC, ATCSCRC1041) in DMEM supplemented with 10% FCS, penicillin, streptomycin and 
L-glutamine at 37 °C and 5%  CO2. Parasites were harvested from recently lysed cell monolayers, passed through 
a 26G needle and a 3 µm TSTP Isopore™ membrane filter and concentrated by centrifugation at 500 g for 10 min. 
The pellet of tachyzoites was re-suspended in sterile PBS. Parasites were counted using a Neubauer hemocytom-
eter and diluted to the required infectious dose in sterile PBS.
Generation of T. gondii ME49 Gra20 and Gra23 knockouts. We employed a CRISPR/Cas9 approach 
to insert frameshifts within the first 20 nt of the start of the coding sequence of gra20 and gra23 in T. gondii Me49 
with consequential disruption of the final translated proteins. Inverse PCR was used to exchange the sgRNA of 
UPRT with the sgRNA for GRA20 with Ph-sgRNA_TgGRA20mutF (5′-ATG CAT AGC CGG AAC TGC GTG TTT 
TAG AGC TAG AAA TAGC-3′) and Ph-genCas9mutR (5′-AAC TTG ACA TCC CCA TTT AC-3′) to yield plasmid 
pCAS9sgGRA20. Similarly, inverse PCR was used to exchange the sgRNA of UPRT with the sgRNA for GRA23 
with Ph-sgRNA_TgGRA23mutF (5′- GCA GCG CGT GCG GGA AGC AGG TTT TAG AGC TAG AAA TAGC-3′) 
and Ph-genCas9mutR (5′-AAC TTG ACA TCC CCA TTT AC-3′) to yield plasmid pCAS9sgGRA23. Transfection 
of T. gondii Me49 was carried out as described  previously89. Twenty-four hours post-transfection, transiently 
transfected  GFP+ parasites were purified by flow cytometry as previously  described90 and individual GRA20 and 
GRA23 KO clones were further purified using two rounds of limiting dilution cloning. Sanger sequencing of 
PCR products was used to confirm disruption of the gra20 and gra23 ORFs.
Infections and monitoring. To isolate T. gondii ME49 bradyzoite containing cysts, the brains of chroni-
cally infected Arc(S) mice (injected i.p. with 500 tachyzoites of T. gondii ME49 > 8 weeks prior) were removed, 
homogenized in sterile PBS, and subjected to centrifugation in a discontinuous Percoll gradient. Cysts were 
counted using a Neubauer hemocytometer and diluted in sterile PBS. For experiments, B6 mice were inoculated 
with 10, 40 or 100 cysts by oral inoculation. For mechanistic studies, B6 mice were injected i.v. in the lateral 
tail vein with  107 tachyzoites of T. gondii ME49, mutant strains on the T. gondii ME49 background or the Type 
II strain T. gondii DEG in a volume of 200 µl. For heat inactivation, T. gondii ME49 tachyzoites were grown as 
described above, enumerated, and washed twice with PBS before incubation at 62º C in a water bath for 1 h. 
Effective killing was verified by addition of heat-killed parasites to a HFF cell monolayer.
All mice were monitored as stipulated by Animal Ethics Committee of James Cook University Approvals 
A2138, A2324. Chronically infected Arc(S) mice were monitored weekly for signs of morbidity and were eutha-
nized using carbon dioxide asphyxiation for brain cyst harvesting. Mice infected orally with T. gondii-containing 
brain cysts were monitored daily for signs of disease and were euthanized using carbon dioxide asphyxiation 
at distinct time-points after infection for immunological readouts or when ethical endpoints were reached for 
survival experiments. Death was never used as an endpoint. Mice infected i.v. or i.p. with T. gondii tachyzoites 
were monitored daily for signs of disease and were euthanized using carbon dioxide asphyxiation 2 to 72 h after 
infection.
Isolation of leukocytes. Spleens, mesenteric lymph nodes and Peyer’s Patches were extracted and mechan-
ically disrupted by pushing cells through a 70 µm cell strainer. Subsequently, red-cell depleted, single-cell sus-
pensions were prepared as described  elsewhere39. Lamina propria cells were isolated from the ileum as published 
previously with minor  modifications91.
Scoring of pathology. Gross pathology of ileum and liver was scored visually using a scoring system 
adapted from Melgar et al.92. For the ileum, the consistency of the intestinal contents, the degree of swelling and 
amount of angiogenesis were assessed. This system is based on an ascending scale of severity, for each parameter, 
as follows: 0 (no abnormality),1 (minimal),2 (moderate),or 3 (severe). For the liver, the colour and appearance 
of the organ were assessed on an ascending scale of severity from 0 (normal colour and appearance); 1 (blotchy 
appearance with some areas exhibiting change in colour); 2 (entire organ pale in colour); or 3 (entire organ pale 
in colour with visible signs of necrosis). Scores for each parameter were added together to give a total score for 
each animal.
Parasite burden. Parasite burden was measured in the whole spleen of individual mice using a microtitre 
dilution method adapted from Buffet et al.93 It was necessary to determine parasite burden in the spleen rather 
than the intestine because it was impossible to harvest immune cells for analysis from the intestine and deter-
mine parasite burden in the same animal, however, we have demonstrated previously that the parasite burden in 
the spleen accurately mirrors that in the  intestine50. Briefly, prior to the experiment, 96 well plates were seeded 
with HFF cells and allowed to become confluent. One row was allocated per mouse and each mouse was done in 
duplicate. Spleens were removed and single-cell suspensions were made by passing through a 70-µm cell strainer. 
Cells were pelleted at 1500g, and then resuspended in RPMI 1,640 containing 5% FCS at a concentration of 
1 × 107 cells/ml. Two hundred microliters of spleen cell suspension was added to the first well of a 96-well plate 
and then serially diluted 1/2 across the plate. Plates were incubated at 37 °C in 5% CO2 for 7 days before wells 
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were examined for the presence of parasites. A score of parasite burden was allocated based on the last column 
in which parasites were visible.
Flow cytometry. To assess expression of surface antigens and IFN-γ secretion, viable, red blood cell-
depleted single-cell suspensions were stained with monoclonal antibodies (all from BD Pharmingen) against 
CD4 (clone GK1.5), CD8α (clone 53-6.7), CD3 (clone 145-2C11), NKp46 (clone 29A1.4), CD44 (clone 1M7), 
CD90.1 (clone 30-H12), CD11b (clone M1/70), CD11c (clone HL3), MHC-II (clone M5/114), Ly6G (clone 
1A8), Ly6C (clone AL-21), CD19 (clone 1D3), F4/80 (clone BM8), or IFN-γ detection antibody (Miltenyi Biotec, 
Germany), IL-18Ralpha (R&D Systems) or IL-12Rbeta1 (CD212, BD).  CD3+CD4+CD25+Foxp3+ regulatory T 
cells were identified using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience). After washing the 
cells, samples were analyzed using a FACSCantoII or FortessaX20 analyzers (BD Biosciences, CA). Propidium 
iodide (2 μg/ml) or Fixable Viability Dye e780 (BD) was added to exclude dead cells. Flow cytometry data were 
analyzed using FlowJo software (Treestar, CA). For all flow cytometry-based analyses, cells were first gated on 
singlets, followed by dead cell exclusion, scatter characteristics and surface marker expression. All samples con-
tained Blank Calibration Particles (BD) to allow cell enumeration.
Assessment of ex vivo IFN‑γ secretion. Ex vivo IFN-γ secretion by distinct lymphocyte subsets was 
assessed as described  previously29. Briefly, mice were injected i.v., i.p., or p.o. with different doses of T. gon-
dii ME49 cysts or tachyzoites (as described in figure legends). At different time points after injection of para-
sites (as described in figure legends), organs were removed aseptically, single cell suspensions were prepared 
and red blood cells were lysed. Cells  (106 were stained with the ‘Mouse IFN-γ secretion assay detection kit’ 
(Miltenyi Biotec, Germany) according to the manufacturer’s instructions and IFN-γ secretion was analyzed by 
flow cytometry. Cells were first gated on live, single lymphocytes, followed by separation into  CD3+NKp46− 
and  CD3−NKp46+ cells.  CD3+NKp46− cells were further gated into  CD4+,  CD8+ and  CD4−CD8− subsets. 
 CD3−NKp46+,  CD3+NKp46−CD4+,  CD3+NKp46−CD8+ and  CD3+NKp46−CD4−CD8− cells were assessed for 
IFN-γ secretion.
Detection of in vivo inflammasome activation by flow cytometry. Detection of apoptosis-associ-
ated speck-like protein containing a caspase recruitment domain (ASC) assembly was performed as described 
 previously94. Briefly, mice were injected with  107 T. gondii ME49-RFP tachyzoites and euthanased 24 h later. 
Cells were stained for surface molecules, fixed, permeabilized and stained with rabbit anti-ASC antibody (Santa 
Cruz Biotechnology) for 45 min at room temperature. Subsequently, a secondary anti-rabbit Alexa488 antibody 
(Life Technologies) was added for 45 min at room temperature. A FMO control without anti-goat Alexa488 was 
included.
Detection of active caspase-1 by flow cytometry was performed using the carboxyfluorescein FLICA kit 
(FAM-YVAD-FMK, Immunochemistry Techniques, Bloomington, MN). B6 mice were injected with  107 T. gondii 
ME49-RFP tachyzoites and 23 h later FAM-YVAD-FMK (diluted in DMSO and PBS) was injected intravenously. 
Splenic cells were analyzed by FACS 1 h later as described above (24 h after T. gondii ME49-RFP injection). Mice 
that received T. gondii ME49-RFP but no FAM-YVAD-FMK were used as FMO control.
Single cells were gated for RFP expression and  RFP+ cells were analyzed for expression of neutrophil, mac-
rophage, monocyte, dendritic cell, T cell and B cell specific surface markers and positivity in green fluorescence 
as shown in Fig. 4.
Multiplex and ELISA. Blood for serum analysis was taken post mortem from the aorta abdominalis and 
collected in serum separator tubes (BD), left for 30  min at room temperature, followed by centrifugation at 
12,000 g for 3 min. Sera were stored at –20 °C until analysis. Measurements were performed using CBA (BD 
Biosciences, CA) or ELISA (elisakit.com, Australia) according to manufacturers’ instructions. Samples were 
acquired on a FACSCantoII (BC Biosciences, CA) or a FLUOstar Omega ELISA Reader (BMG Labtech).
IL‑2/anti‑IL‑2 complex‑mediated cell expansion. IL-2/anti-IL-2 complexes (IL2C) were prepared as 
described  previously38. Briefly, 1.5 µg of recombinant mouse IL-2 (Peprotech) and 10 µg of anti-IL-2 mAb (clone 
S4B6, Walter and Eliza Hall Institute [WEHI] antibody facility, Melbourne, Australia) were mixed, incubated at 
37 °C for 30 min, and administered i.p. in a volume of 200 µl for four consecutive days. Mice were monitored and 
weighed daily during the IL2C treatment period.
Antibody‑mediated cell depletion and cytokine neutralization. For cytokine neutralization and 
cell depletion, monoclonal antibodies against IL-12, IL-18, IFN-γ, CD8, NK1.1, Thy1.2 and rat IgG were pur-
chased from the WEHI antibody facility or from BioXCell (NH, USA). A total of 200 µg of anti-IL-18 (clone 
YIGIF74-1G7; Cat. No.: BE0237), anti-IFN-γ (clone HB170-15), anti-IL12 (clone C17.8), anti-NK1.1 (clone 
PK136), anti-CD8 (clone 2.43), anti-Thy1.2 (clone 30H12) or control rat IgG were injected i.p. weekly in a vol-
ume of 200 µl.
Statistics. Statistical analysis was performed using GraphPad Prism, GraphPad software, San Diego, CA 
as indicated in individual figure legends. These included: one-way analysis of variance (ANOVA), followed by 
Dunnett’s multiple comparison test for most data sets; two-way ANOVA followed by Tukey’s post hoc test for 
data presented in Fig. 3; two-tailed Student’s t tests for data presented in Fig. 7i; a Log-rank (Mantel–Cox) test 
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to compare significance for survival experiments in Figs. 7b,c,e,f. A P value of less than 0.05 was considered 
significant.
Ethics statement. All experiments were approved and conducted according to Australian animal pro-
tection law and in accordance with requirements of the Animal Ethics Committee of James Cook University 
(Approvals A2138, A2324). Death was never used as an endpoint.
Data availability
All data are available within the manuscript and Supplementary Information.
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